Final countdown: How to transition your trials under EU-CTR
Parexel's regulatory experts shared their insight how to transition trials under EU-CTR in a live webinar on April 30. Watch on-demand to find out more about:
- The processes and timescales required to meet the EU-CTR trial transition deadline of 31 January 2025
- Actions that sponsors should take for a smooth transition process and to mitigate the risk of non-compliance as a result of missing the deadline
- Key learnings, insights and tips from regulatory experts with practical experience in how to approach the transition process
- Answers to the queries raised by our audience during the Q&A session
With the deadline for transition approaching fast, we're urging sponsors to begin the transition process for their their trials now to mitigate potential delays and the risk of trials ceasing through non-compliance with EU-CTR.
Related Insights
Blog
EMA’s evolving stance on external controls: Key takeaways and preparation strategies for sponsors
Dec 10, 2025
Blog
The EU-CTR transition: Four key ways to prepare now
Jan 12, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Related Insights
Blog
EMA’s evolving stance on external controls: Key takeaways and preparation strategies for sponsors
Dec 10, 2025
Blog
The EU-CTR transition: Four key ways to prepare now
Jan 12, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023